AU2007256754B2 - Myxoma virus mutants for cancer treatment - Google Patents
Myxoma virus mutants for cancer treatment Download PDFInfo
- Publication number
- AU2007256754B2 AU2007256754B2 AU2007256754A AU2007256754A AU2007256754B2 AU 2007256754 B2 AU2007256754 B2 AU 2007256754B2 AU 2007256754 A AU2007256754 A AU 2007256754A AU 2007256754 A AU2007256754 A AU 2007256754A AU 2007256754 B2 AU2007256754 B2 AU 2007256754B2
- Authority
- AU
- Australia
- Prior art keywords
- myxoma virus
- activity
- cancer
- myxoma
- deficient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241000700562 Myxoma virus Species 0.000 title claims abstract description 80
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 38
- 201000011510 cancer Diseases 0.000 title claims abstract description 37
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 29
- 230000000694 effects Effects 0.000 claims abstract description 28
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 26
- 230000002950 deficient Effects 0.000 claims abstract description 19
- 206010018338 Glioma Diseases 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 15
- 208000032612 Glial tumor Diseases 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 3
- 102220361483 c.31A>T Human genes 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 28
- 241000700605 Viruses Species 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000010076 replication Effects 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 101150061325 mv gene Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 241001529936 Murinae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24061—Methods of inactivation or attenuation
- C12N2710/24062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80364006P | 2006-06-01 | 2006-06-01 | |
| US60/803,640 | 2006-06-01 | ||
| PCT/US2007/070219 WO2007143548A2 (en) | 2006-06-01 | 2007-06-01 | Myxoma virus mutants for cancer treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2007256754A1 AU2007256754A1 (en) | 2007-12-13 |
| AU2007256754B2 true AU2007256754B2 (en) | 2012-11-29 |
Family
ID=38802246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007256754A Ceased AU2007256754B2 (en) | 2006-06-01 | 2007-06-01 | Myxoma virus mutants for cancer treatment |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8512713B2 (enExample) |
| EP (3) | EP3254694A1 (enExample) |
| JP (4) | JP2009538935A (enExample) |
| KR (1) | KR20090014364A (enExample) |
| CN (1) | CN101460194B (enExample) |
| AU (1) | AU2007256754B2 (enExample) |
| CA (2) | CA2652228C (enExample) |
| IL (1) | IL195297A (enExample) |
| MX (1) | MX2008015265A (enExample) |
| NZ (1) | NZ572893A (enExample) |
| WO (1) | WO2007143548A2 (enExample) |
| ZA (1) | ZA200809769B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007256754B2 (en) | 2006-06-01 | 2012-11-29 | Robarts Research Institute | Myxoma virus mutants for cancer treatment |
| FR2946536B1 (fr) * | 2009-06-11 | 2011-07-29 | Agronomique Inst Nat Rech | Utilisation d'une souche attenuee de myxoma virus comme oncolytique |
| US12128099B2 (en) | 2018-05-25 | 2024-10-29 | Bioventures, Llc | Myxoma virus compositions and methods of use |
| EP3846829A4 (en) * | 2018-09-05 | 2022-09-14 | Arizona Board of Regents on behalf of Arizona State University | ONCOLYTIC VIRUS PLATFORM FOR THE TREATMENT OF HEMATOLOGICAL CANCER |
| WO2020106880A1 (en) | 2018-11-20 | 2020-05-28 | Bioventures, Llc | Cells for the production of viruses and methods of using the same |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ518945A (en) | 1997-10-09 | 2007-03-30 | Wellstat Biologics Corp | Treatment of neoplasms with viruses |
| ES2153284B1 (es) | 1998-06-10 | 2001-09-01 | Fundacion Para El Estudio Y De | Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos. |
| AU4246900A (en) | 1999-04-15 | 2000-11-02 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| EP1200595A2 (en) | 1999-07-12 | 2002-05-02 | Viron Therapeutics, Inc. | Myxoma virus genes for immune modulation |
| WO2001087324A1 (en) | 2000-05-17 | 2001-11-22 | Viron Therapeutics, Inc. | Compositions and methods for promoting immunosuppression |
| DE60209345T2 (de) * | 2001-03-08 | 2006-08-03 | Akzo Nobel N.V. | Leporipox-basierende vektorvakzine |
| US7582614B2 (en) * | 2003-03-07 | 2009-09-01 | Robarts Research Institute | Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection |
| NZ550430A (en) | 2004-04-27 | 2009-06-26 | Wellstat Biologics Corp | Cancer treatment using viruses and camptothecins |
| DK2388315T3 (da) * | 2005-03-07 | 2014-08-25 | Univ Western Ontario | Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling |
| WO2007143545A2 (en) | 2006-06-01 | 2007-12-13 | Robarts Research Institute | Tnf signaling in myxoma virus treatments |
| AU2007256754B2 (en) | 2006-06-01 | 2012-11-29 | Robarts Research Institute | Myxoma virus mutants for cancer treatment |
| WO2007147118A1 (en) | 2006-06-16 | 2007-12-21 | Robarts Research Institute | Infection of cells with myxoma virus requires akt activation |
-
2007
- 2007-06-01 AU AU2007256754A patent/AU2007256754B2/en not_active Ceased
- 2007-06-01 CA CA2652228A patent/CA2652228C/en not_active Expired - Fee Related
- 2007-06-01 EP EP17182211.7A patent/EP3254694A1/en not_active Withdrawn
- 2007-06-01 CN CN2007800202887A patent/CN101460194B/zh not_active Expired - Fee Related
- 2007-06-01 EP EP07798014A patent/EP2021023A4/en not_active Withdrawn
- 2007-06-01 EP EP11184754.7A patent/EP2457584B1/en not_active Not-in-force
- 2007-06-01 KR KR1020087029274A patent/KR20090014364A/ko not_active Ceased
- 2007-06-01 JP JP2009513472A patent/JP2009538935A/ja not_active Withdrawn
- 2007-06-01 NZ NZ572893A patent/NZ572893A/en not_active IP Right Cessation
- 2007-06-01 MX MX2008015265A patent/MX2008015265A/es active IP Right Grant
- 2007-06-01 WO PCT/US2007/070219 patent/WO2007143548A2/en not_active Ceased
- 2007-06-01 CA CA2951453A patent/CA2951453A1/en not_active Abandoned
- 2007-06-01 US US12/301,961 patent/US8512713B2/en not_active Expired - Fee Related
-
2008
- 2008-11-13 ZA ZA200809769A patent/ZA200809769B/xx unknown
- 2008-11-13 IL IL195297A patent/IL195297A/en active IP Right Grant
-
2013
- 2013-03-01 JP JP2013040387A patent/JP5665899B2/ja not_active Expired - Fee Related
- 2013-08-19 US US13/969,853 patent/US20130336930A1/en not_active Abandoned
-
2014
- 2014-12-09 JP JP2014248831A patent/JP2015044878A/ja active Pending
-
2016
- 2016-01-21 US US15/002,971 patent/US9980994B2/en active Active
- 2016-10-06 JP JP2016197808A patent/JP2017008105A/ja active Pending
Non-Patent Citations (2)
| Title |
|---|
| Graham K A, Virology, vol 191, no 1, 1 November 1992, pages 112-124 * |
| Opgenorth A et al, J of Virology, vol 66, no 8, 1992, pages 4720-4731 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US9980994B2 (en) | 2018-05-29 |
| JP2013100370A (ja) | 2013-05-23 |
| EP2021023A2 (en) | 2009-02-11 |
| IL195297A (en) | 2015-04-30 |
| KR20090014364A (ko) | 2009-02-10 |
| MX2008015265A (es) | 2008-12-12 |
| CN101460194A (zh) | 2009-06-17 |
| US20110158945A1 (en) | 2011-06-30 |
| AU2007256754A1 (en) | 2007-12-13 |
| EP2457584A1 (en) | 2012-05-30 |
| US8512713B2 (en) | 2013-08-20 |
| JP2017008105A (ja) | 2017-01-12 |
| CA2951453A1 (en) | 2007-12-13 |
| EP2457584B1 (en) | 2017-08-09 |
| US20130336930A1 (en) | 2013-12-19 |
| CN101460194B (zh) | 2013-08-14 |
| US20160136212A1 (en) | 2016-05-19 |
| JP2009538935A (ja) | 2009-11-12 |
| ZA200809769B (en) | 2009-07-29 |
| EP3254694A1 (en) | 2017-12-13 |
| JP5665899B2 (ja) | 2015-02-04 |
| EP2021023A4 (en) | 2010-08-11 |
| WO2007143548A2 (en) | 2007-12-13 |
| CA2652228C (en) | 2017-07-11 |
| NZ572893A (en) | 2011-06-30 |
| CA2652228A1 (en) | 2007-12-13 |
| IL195297A0 (en) | 2009-08-03 |
| WO2007143548A3 (en) | 2008-09-25 |
| JP2015044878A (ja) | 2015-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Markert et al. | Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir | |
| US9980994B2 (en) | Myxoma virus mutants for cancer treatment | |
| Sampath et al. | Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects | |
| Alkayyal et al. | SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus | |
| EP2388315B1 (en) | Use of a Myxoma virus that does not express functional M135R for therapeutic treatment | |
| Liu et al. | Selective editing of herpes simplex virus 1 enables interferon induction and viral replication that destroy malignant cells | |
| Gridley et al. | Evaluation of radiation effects against C6 glioma in combination with vaccinia virus-p53 gene therapy. | |
| Lockart Jr | The production and maintenance of a virus carrier state: The possible role of homologous interference | |
| JPH06504450A (ja) | ヒトあるいは動物有機体を措置するための細胞組成物 | |
| Steele et al. | Reovirus type 3 chemoimmunotherapy of murine lymphoma is abrogated by cyclosporine | |
| HK1247113A1 (en) | Myxoma virus mutants for cancer treatment | |
| HK1170951A (en) | Myxoma virus mutants for cancer treatment | |
| Ishikawa et al. | NKT cells are responsible for the clearance of murine norovirus through the virus-specific secretory IgA pathway | |
| US20220273739A1 (en) | Combination drug for treating malignant tumor, pharmaceutical composition for treating malignant tumor, and pharmaceutical composition for malignant tumor treatment | |
| DePeaux et al. | Treatment with oncolytic vaccinia virus infects tumor-infiltrating regulatory and exhausted T cells | |
| Ding et al. | Evaluation of tumor specificity and immunity of thymidine kinase-deleted vaccinia virus guang9 strain | |
| Guayasamin et al. | Type III interferon attenuates a vesicular stomatitis virus-based vaccine vector | |
| Nikolaeva et al. | Sensitivity of Primary Human Glioblastoma Cell Lines to the Mumps Virus Vaccine Strain | |
| Scheicher | Oncolytic Virotherapy of Neuroendocrine Neoplasms with oncolytic measles vaccine virus | |
| CN116870014A (zh) | 贝母甲素在制备溶瘤病毒抗肿瘤增效剂中的应用以及包含贝母甲素的组合物 | |
| Pusateri | Nonspecific inhibition of encephalomyocarditis virus replication by immune interferon released from unstimulated cells of mice sensitized with nonviable Mycobacterium tuberculosis | |
| Lin et al. | Antagonistic action of retinoic acid against teleocidin and 12-O-tetradecanoyl-phorbol-13-acetate on activation of Epstein-Barr virus genomes | |
| Baird | Development of a Novel Model for Exploring the Role of Regulatory T-cells in Oncolytic HSV Cancer Therapy | |
| HK1163175B (en) | Use of a myxoma virus that does not express functional m135r for therapeutic treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |